alexa
Reach Us 44-1522-440391
Circulating Tumor Cells as Prognostic Marker in Japanese patients with Kras Wild-type Metastatic Colorectal Cancer Receiving Panitumumab after Progression on Cetuximab | Abstract
ISSN: 2157-7099

Journal of Cytology & Histology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Circulating Tumor Cells as Prognostic Marker in Japanese patients with Kras Wild-type Metastatic Colorectal Cancer Receiving Panitumumab after Progression on Cetuximab

Yoshihito Ohhara1,2, Satoshi Matsusaka1,3*, Toshiyasu Watanabe1, Eiji Shinozaki1, Mitsukuni Suenaga1, Nobuyuki Mizunuma1 and Kiyohiko Hatake3

1Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

2Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan

3Cancer Chemotherapy Center, Clinical Chemotherapy, Japanese Foundation for Cancer Research, Tokyo, Japan

*Corresponding Author:
Satoshi Matsusaka
Department of Gastroenterology
Cancer Institute Hospital
Japanese Foundation for Cancer Research
3-8-31 Ariake, Koto-ku
Tokyo, Japan
Tel: +81-3-3520-0111
Fax: +81-3-3570-0343
E-mail: [email protected]

Received Date: November 14, 2013; Accepted Date: December 09, 2013; Published Date: December 11, 2013

Citation: Ohhara Y, Matsusaka S, Watanabe T, Shinozaki E, Suenaga M, et al. (2013) Circulating Tumor Cells as Prognostic Marker in Japanese patients with Kras Wild-type Metastatic Colorectal Cancer Receiving Panitumumab after Progression on Cetuximab. J Cytol Histol 5:204. doi:10.4172/2157-7099.1000204

Copyright: © 2013 Ohhara Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Panitumumab has a high affinity for epidermal growth factor receptor. Its utility as a salvage therapy is unknown in cetuximab-resistant colorectal cancer. We assessed the prognostic and predictive role of circulating tumor cells (CTCs) in KRAS wild-type metastatic Colorectal Cancer (mCRC) patients treated with panitumumab after progression on cetuximab.
Methods: Panitumumab (6 mg/kg every 2 weeks) was administered as salvage therapy in a patient with cetuximab-resistant mCRC. The CTC count in whole blood at baseline was determined using immunomagnetics.
Results: Nineteen patients were enrolled in the study between July 2010 and March 2011. Five patients had Stable Disease (SD) with a response rate of 0%. Four patients reached long-SD, which was defined as continuous SD of more than 120 days. All of these four patients had <2 CTCs. Multivariate analysis revealed that ≥2 CTCswas an independent predictor of Progression-Free Survival (PFS) (hazard ratio: 7.275, P=0.013). Patients with ≥2 CTCs had a shorter median PFS than those with <2 CTCs (1.8 versus 3.6 months, P=0.008). No statistically significant difference was observed in median overall survival between patients with ≥2 CTCs and those with <2 CTCs (3.2 versus 6.7 months, P=0.164).
Conclusions
: These results suggest that <2 CTCs indicates that panitumumab may be effective in patients with KRAS-wild-type mCRC after progression on cetuximab.

Keywords

Top